Recent studies using 30% as the cut-off Ki67 value for stratified analysis have likewise determined that a high Ki67 score (30%) is a potential prognostic marker and predictor of neoadjuvant or adjuvant chemotherapy efficacy in breast cancer and other malignant diseases (12–16). Here, MKI67 is linked to breast carcinoma.